{
    "medicine_id": "791dc3d3a1efe336319113828009a6462e0ec347",
    "platform_id": "DB14146",
    "metadata": {
        "name": "ARTEMES 3R Effect Hyaluronic Ampoule 0 000045 mg 45mg Solution",
        "composition": "0 000045 mg 45mg Loxicodegol",
        "clinical_particulars": {
            "therapeutic_indications": "Loxicodegol was developed as an opioid analgesic with low abuse potential for use in treating chronic pain L3263 An application has been filed for FDA approval of Loxicodegol for use in treating chronic lower back pain",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Loxicodegol displays full analgesic activity comparable to that of oxycodone producing similar acetone writhing test responses in mice and hot plate test maximal latencies in rats A34016 The safety profile of Loxicodegol is much improved from that of other opioid analgesics A33997 The incidence of respiratory depression and sedation is reduced compared to oxycodone and morphine Generalized pruritus occurred in 7 3 and 4 9 of subjects at 200mg and 400mg of Loxicodegol compared to 41 5 with 40mg oxycodone Nausea occurred in 2 5 2 4 and 7 3 with 100mg 200mg and 400mg of Loxecodegol compared to 29 3 with 40mg oxycodone Lastly vomiting occurred in 2 4 with both 200mg and 400mg Loxicodegol compared to 24 4 with 40mg oxycodone Loxicodegol is much less addictive than other opioid analgesics It produces a only a slight high at dosages of 400mg peaking at scores only 25 that of oxycodone with no difference compared to placebo at lower dosages No differences have been noted between Loxicodegol and saline in self administration or behavior reinforcement in monkeys or rats A33997 A34016",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}